TEVA PHARMACEUTICAL INDUSTRIES LIMITED Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-04-19: Measure Non-GAAP Operating Profit.
- 2023-04-19: Measure Net Revenue.
- 2023-04-19: Measure Relative TSR.
- 2023-04-19: Measure Non-GAAP Earnings Per Share.
| Proxy filed | Measure |
|---|---|
| 2023-04-19 | Non-GAAP Operating Profit |
| 2023-04-19 | Net Revenue |
| 2023-04-19 | Relative TSR |
| 2023-04-19 | Non-GAAP Earnings Per Share |
| 2023-04-19 | Free Cash Flow |
| 2024-04-16 | Non-GAAP Operating Income |
| 2024-04-16 | Net Revenue from Innovative Products |
| 2024-04-16 | Net Revenue from All Other Products |
| 2024-04-16 | Relative TSR |
| 2024-04-16 | Non-GAAP Earnings Per Share |
| 2024-04-16 | Free Cash Flow |
| 2025-04-09 | Net Revenue |
| 2025-04-09 | Free Cash Flow |
| 2025-04-09 | Non-GAAP Earnings Per Share |
| 2025-04-09 | Stock Price |
| 2026-03-31 | Net Revenue |
| 2026-03-31 | Free Cash Flow |
| 2026-03-31 | Non-GAAP Earnings Per Share |
| 2026-03-31 | Stock Price |